Cohance Lifesciences [COHANCE] Slumps on Weak Q4, Brokerages Divided

Shares of Cohance Lifesciences [COHANCE] experienced a notable decline, dropping by approximately 7% following the announcement of its Q4 results for the March quarter. The pharmaceutical company reported a substantial 84% year-on-year drop in net profit, significantly impacting investor sentiment.

Adding to the downward pressure, Jefferies downgraded Cohance Lifesciences [COHANCE] to an "Underperform" rating, effectively a REDUCE call. While a new target price was not explicitly provided in the details, Jefferies also cut its target price, citing concerns over management instability and weak visibility for the company's future performance. This cautious stance reflects potential challenges ahead for Cohance Lifesciences.

In contrast, Goldman Sachs maintained its "Buy" rating on Cohance Lifesciences [COHANCE], indicating a belief in the company's long-term potential. Despite acknowledging the near-term challenges and the recent weak financial performance, Goldman Sachs appears to be focusing on the company's underlying business opportunities over a longer horizon.

The divergent views from these prominent brokerages highlight the complex outlook for Cohance Lifesciences [COHANCE]. Investors are grappling with immediate concerns stemming from the steep profit decline and management uncertainties, balanced against potential long-term growth prospects envisioned by some analysts.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions. StockTips.in is not a SEBI-registered investment advisor.